Previous 10 |
Inhibitor Therapeutics, Inc. Exclusive License with Johns Hopkins University PR Newswire A critical milestone completed on the mission path of commercializing Itraconazole in numerous oncology indications. TAMPA, Fla. , Dec. 13, 2023 /PRNewswire/ -- Inhibitor...
INVO BioScience Inc. (INVO) is expected to report for Q3 2023 HIVE Blockchain Technologies Ltd (HIVE) is expected to report $-0.13 for Q2 2024 BioNexus Gene Lab Corp (BGLC) is expected to report for Q1 2024 Adhera Therapeutics Inc (ATRX) is expected to report for Q1 2024 Altus Pow...
Inhibitor Therapeutics Inc (INTI) is expected to report for Q1 2024
TAMPA, Fla. , Jan. 22, 2020 /PRNewswire/ -- INHIBITOR Therapeutics, Inc. (OTCQB: INTI) , a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to inhibit progression of cancerous and non-cancerous prolifera...
News, Short Squeeze, Breakout and More Instantly...
Inhibitor Therapeatics Inc Company Name:
INTI Stock Symbol:
OTCMKTS Market:
GD Culture Group Limited (GDC) is expected to report for Q4 2023 Citizens Inc. Class A ($1.00 Par) (CIA) is expected to report for quarter end 2023-12-31 Escalade Incorporated (ESCA) is expected to report for Q4 2023 Lendway Inc. (LDWY) is expected to report for quarter end 2023-12-31...
Community Bancorp Inc Vermont (CMTV) is expected to report for Q4 2023 CISO Global, Inc (CISO) is expected to report for Q4 2023 TCTM Kids IT Education Inc. (TCTM) is expected to report for quarter end 2023-12-31 Generation Income Properties Inc. (GIPR) is expected to report for quart...
Lendway Inc. (LDWY) is expected to report for quarter end 2023-12-31 Hongchang International Co Ltd Com (New) (HCIL) is expected to report for Q4 2023 BioStem Technologies Inc (BSEM) is expected to report $0.47 for Q4 2023 Nicox SA (NICXF) is expected to report $-0.07 for Q4 2023 ...